Antibody Peptide Based Antifungal Immunotherapy
We addressed the possibility that any fragment of the variable and constant regions may display antifungal (fungicidal and/or immunomodulatory) activity irrespective of the specificity for a given antigen or the isotype of the belonging antibody (Ab). Complementarity determining regions (CDRs)-based...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-06-01
|
Series: | Frontiers in Microbiology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fmicb.2012.00190/full |
id |
doaj-ff085c52d4214eeb9dbaca649436fe5e |
---|---|
record_format |
Article |
spelling |
doaj-ff085c52d4214eeb9dbaca649436fe5e2020-11-24T22:57:46ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2012-06-01310.3389/fmicb.2012.0019028213Antibody Peptide Based Antifungal ImmunotherapyWalter eMagliani0Stefania eConti1Laura eGiovati2Pier Paolo eZanello3Martina eSperindè4Tecla eCiociola5Luciano ePolonelli6University of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyUniversity of Parma - ItalyWe addressed the possibility that any fragment of the variable and constant regions may display antifungal (fungicidal and/or immunomodulatory) activity irrespective of the specificity for a given antigen or the isotype of the belonging antibody (Ab). Complementarity determining regions (CDRs)-based synthetic peptides of recombinant and monoclonal murine and human Abs directed to unrelated epitopes showed differential in vitro and/or in vivo antifungal activities, conceivably mediated by different mechanisms of action. Alanine substituted peptides obtained from fungicidal CDR sequences, and used as surrogates of natural point mutations, showed further differential increased, unaltered or decreased candidacidal activitiy. Candidacidal CDR-related peptides, which proved to be devoid of cytotoxicity on mammalian cells, showed to be characterized in solution by a peculiar self-aggregation-releasing property that could provide protection against proteases and a slow release of the active form over time. An immunomodulatory synthetic peptide related to a CDR proved to exert a therapeutic effect against systemic candidiasis without possessing direct candidacidal properties. Likewise CDR-related peptides, synthetic peptides with sequence identical to fragments putatively deriving from the cleavage of the constant region of Abs proved to display in vitro and/or in vivo fungicidal and/or immunomodulatory antifungal activity. These results open a new scenario about the possibility that Ab fragments may effectively influence the antifungal immune response in a way reminiscent of peptides of innate immunity. It is suggested, moreover, that immunoglobulins (Igs) may be sources of an unlimited number of sequences potentially active against fungal agents and related mycoses.http://journal.frontiersin.org/Journal/10.3389/fmicb.2012.00190/fullAntifungal antibodiesKiller toxinAntibiobodiesSynthetic CDRsKiller peptidesAntifungal peptides |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Walter eMagliani Stefania eConti Laura eGiovati Pier Paolo eZanello Martina eSperindè Tecla eCiociola Luciano ePolonelli |
spellingShingle |
Walter eMagliani Stefania eConti Laura eGiovati Pier Paolo eZanello Martina eSperindè Tecla eCiociola Luciano ePolonelli Antibody Peptide Based Antifungal Immunotherapy Frontiers in Microbiology Antifungal antibodies Killer toxin Antibiobodies Synthetic CDRs Killer peptides Antifungal peptides |
author_facet |
Walter eMagliani Stefania eConti Laura eGiovati Pier Paolo eZanello Martina eSperindè Tecla eCiociola Luciano ePolonelli |
author_sort |
Walter eMagliani |
title |
Antibody Peptide Based Antifungal Immunotherapy |
title_short |
Antibody Peptide Based Antifungal Immunotherapy |
title_full |
Antibody Peptide Based Antifungal Immunotherapy |
title_fullStr |
Antibody Peptide Based Antifungal Immunotherapy |
title_full_unstemmed |
Antibody Peptide Based Antifungal Immunotherapy |
title_sort |
antibody peptide based antifungal immunotherapy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Microbiology |
issn |
1664-302X |
publishDate |
2012-06-01 |
description |
We addressed the possibility that any fragment of the variable and constant regions may display antifungal (fungicidal and/or immunomodulatory) activity irrespective of the specificity for a given antigen or the isotype of the belonging antibody (Ab). Complementarity determining regions (CDRs)-based synthetic peptides of recombinant and monoclonal murine and human Abs directed to unrelated epitopes showed differential in vitro and/or in vivo antifungal activities, conceivably mediated by different mechanisms of action. Alanine substituted peptides obtained from fungicidal CDR sequences, and used as surrogates of natural point mutations, showed further differential increased, unaltered or decreased candidacidal activitiy. Candidacidal CDR-related peptides, which proved to be devoid of cytotoxicity on mammalian cells, showed to be characterized in solution by a peculiar self-aggregation-releasing property that could provide protection against proteases and a slow release of the active form over time. An immunomodulatory synthetic peptide related to a CDR proved to exert a therapeutic effect against systemic candidiasis without possessing direct candidacidal properties. Likewise CDR-related peptides, synthetic peptides with sequence identical to fragments putatively deriving from the cleavage of the constant region of Abs proved to display in vitro and/or in vivo fungicidal and/or immunomodulatory antifungal activity. These results open a new scenario about the possibility that Ab fragments may effectively influence the antifungal immune response in a way reminiscent of peptides of innate immunity. It is suggested, moreover, that immunoglobulins (Igs) may be sources of an unlimited number of sequences potentially active against fungal agents and related mycoses. |
topic |
Antifungal antibodies Killer toxin Antibiobodies Synthetic CDRs Killer peptides Antifungal peptides |
url |
http://journal.frontiersin.org/Journal/10.3389/fmicb.2012.00190/full |
work_keys_str_mv |
AT walteremagliani antibodypeptidebasedantifungalimmunotherapy AT stefaniaeconti antibodypeptidebasedantifungalimmunotherapy AT lauraegiovati antibodypeptidebasedantifungalimmunotherapy AT pierpaoloezanello antibodypeptidebasedantifungalimmunotherapy AT martinaesperinde antibodypeptidebasedantifungalimmunotherapy AT teclaeciociola antibodypeptidebasedantifungalimmunotherapy AT lucianoepolonelli antibodypeptidebasedantifungalimmunotherapy |
_version_ |
1725649303692640256 |